Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotechnology company focused on antibody engineering and therapeutic combinations for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases, has announced its participation in two upcoming investor conferences in March 2025.
The company will attend the TD Cowen 45th Annual Healthcare Conference in Boston on March 4, 2025, where management will participate in a fireside chat at 3:10pm ET and hold one-on-one meetings. Additionally, Spyre will be present at the Jefferies Biotech on the Beach Summit in Miami on March 11, 2025, for one-on-one meetings.
Live audio webcasts and replays of the TD Cowen fireside chat will be available on the company's investor events website at https://ir.spyre.com/events-and-presentations.
Spyre Therapeutics (NASDAQ: SYRE), un'azienda biotecnologica in fase clinica focalizzata sull'ingegneria degli anticorpi e sulle combinazioni terapeutiche per la Malattia Infiammatoria Intestinale (IBD) e altre malattie mediate dal sistema immunitario, ha annunciato la sua partecipazione a due conferenze per investitori in programma a marzo 2025.
L'azienda parteciperà al 45° Congresso Annuale sulla Salute di TD Cowen a Boston il 4 marzo 2025, dove la direzione parteciperà a una chiacchierata informale alle 15:10 ET e terrà incontri individuali. Inoltre, Spyre sarà presente al Jefferies Biotech on the Beach Summit a Miami l'11 marzo 2025, per incontri individuali.
Le dirette audio e le registrazioni della chiacchierata informale di TD Cowen saranno disponibili sul sito web degli eventi per investitori dell'azienda all'indirizzo https://ir.spyre.com/events-and-presentations.
Spyre Therapeutics (NASDAQ: SYRE), una empresa biotecnológica en etapa clínica centrada en la ingeniería de anticuerpos y combinaciones terapéuticas para la Enfermedad Inflamatoria Intestinal (IBD) y otras enfermedades mediadas por el sistema inmunológico, ha anunciado su participación en dos conferencias de inversores programadas para marzo de 2025.
La empresa asistirá a la 45ª Conferencia Anual de Salud de TD Cowen en Boston el 4 de marzo de 2025, donde la dirección participará en una charla informal a las 3:10 p.m. ET y llevará a cabo reuniones individuales. Además, Spyre estará presente en la Cumbre Jefferies Biotech on the Beach en Miami el 11 de marzo de 2025, para reuniones uno a uno.
Las transmisiones de audio en vivo y las repeticiones de la charla informal de TD Cowen estarán disponibles en el sitio web de eventos para inversores de la empresa en https://ir.spyre.com/events-and-presentations.
Spyre Therapeutics (NASDAQ: SYRE)는 항체 공학 및 염증성 장 질환 (IBD)과 기타 면역 매개 질환을 위한 치료 조합에 집중하는 임상 단계 생명공학 회사로, 2025년 3월에 예정된 두 개의 투자자 회의에 참여한다고 발표했습니다.
회사는 2025년 3월 4일 보스턴에서 열리는 TD Cowen 제45회 연례 헬스케어 회의에 참석하며, 경영진은 오후 3시 10분 ET에 진행되는 파이어사이드 차트에 참여하고 일대일 미팅을 진행할 것입니다. 또한, Spyre는 2025년 3월 11일 마이애미에서 열리는 Jefferies Biotech on the Beach Summit에 참석하여 일대일 미팅을 진행할 예정입니다.
TD Cowen의 파이어사이드 차트는 회사의 투자자 이벤트 웹사이트에서 실시간 오디오 웹캐스트 및 재생으로 제공될 예정이며, 주소는 https://ir.spyre.com/events-and-presentations입니다.
Spyre Therapeutics (NASDAQ: SYRE), une entreprise de biotechnologie en phase clinique spécialisée dans l'ingénierie des anticorps et les combinaisons thérapeutiques pour la Maladie Inflammatoire Intestinale (IBD) et d'autres maladies médiées par le système immunitaire, a annoncé sa participation à deux conférences pour investisseurs prévues en mars 2025.
L'entreprise assistera à la 45e Conférence Annuelle sur la Santé de TD Cowen à Boston le 4 mars 2025, où la direction participera à une discussion informelle à 15h10 ET et tiendra des réunions individuelles. De plus, Spyre sera présent au Sommet Jefferies Biotech on the Beach à Miami le 11 mars 2025, pour des réunions individuelles.
Des webcasts audio en direct et des rediffusions de la discussion informelle de TD Cowen seront disponibles sur le site des événements pour investisseurs de l'entreprise à l'adresse https://ir.spyre.com/events-and-presentations.
Spyre Therapeutics (NASDAQ: SYRE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Antikörperengineering und therapeutische Kombinationen für Entzündliche Darmerkrankungen (IBD) und andere immunvermittelte Krankheiten konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im März 2025 bekannt gegeben.
Das Unternehmen wird am 45. jährlichen Gesundheitskongress von TD Cowen in Boston am 4. März 2025 teilnehmen, wo das Management um 15:10 Uhr ET an einem Fireside-Chat teilnehmen und Einzelgespräche führen wird. Darüber hinaus wird Spyre am Jefferies Biotech on the Beach Summit in Miami am 11. März 2025 für Einzelgespräche anwesend sein.
Live-Audio-Webcasts und Wiederholungen des Fireside-Chats von TD Cowen werden auf der Website der Investorenveranstaltungen des Unternehmens unter https://ir.spyre.com/events-and-presentations verfügbar sein.
- Spyre Therapeutics is actively engaging with investors through participation in prestigious healthcare conferences
- The company is providing accessibility to investors through both in-person meetings and webcasted events
- Spyre is developing potentially best-in-class treatments for inflammatory bowel disease and other immune-mediated conditions
- The press release doesn't provide specific updates on clinical progress or pipeline developments
- No financial information or business updates were included in the announcement
- The company is still in clinical-stage with no mention of marketed products or revenue generation
Event: TD Cowen 45th Annual Healthcare Conference
Format: Fireside chat and 1x1 meetings
Date/Time: Tuesday, March 4, 2025 at 3:10pm ET
Location:
Event: Jefferies Biotech on the Beach Summit
Format: 1x1 meetings
Date: Tuesday, March 11, 2025
Location:
Live audio webcasts and replays of the TD Cowen fireside event will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-upcoming-march-investor-conferences-302383597.html
SOURCE Spyre Therapeutics, Inc.
FAQ
When is Spyre Therapeutics (SYRE) presenting at the TD Cowen Healthcare Conference?
Where can investors watch Spyre Therapeutics' (SYRE) March 2025 conference presentations?
What investor conferences will Spyre Therapeutics (SYRE) attend in March 2025?
What therapeutic areas does Spyre Therapeutics (SYRE) focus on?
Will Spyre Therapeutics (SYRE) offer one-on-one meetings at the March 2025 conferences?
